May 9, 2006
Cougar Biotechnology Announces Presentation at Rodman & Renshaw 3rd Annual Global Healthcare Conference
Los Angeles, CA, May 9, 2006 -
Cougar Biotechnology, Inc, a publicly held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16th at 9:25 AM Central European Summer Time (CEST) at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Mr. Auerbach will provide a company overview and update on the status of Cougar’s current clinical development programs.
A live webcast of the presentation can be accessed on the Company’s website at www.cougarbiotechnology.com. The presentation will also be archived shortly after the live event and available online for 90 days following the conference.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar’s oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme which is currently being tested in a Phase I clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and the Company's reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.
Contact
Alan H. Auerbach, Cougar Biotechnology, Inc.
+1 310 943 8040
ahauerbach@cougarbiotechnology.com
|
Dedicated to Innovative Treatments...
|
|
